Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Dermata Therapeutics, Inc. - Common Stock
(NQ:
DRMA
)
3.970
-0.020 (-0.50%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dermata Therapeutics, Inc. - Common Stock
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
July 01, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
July 01, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
July 01, 2022
Good morning, trader! It's time for another look at the biggest pre-market stock movers as we dive into the latest news for Friday!
Via
InvestorPlace
Akebia Therapeutics And 20 Stocks Moving Premarket
July 01, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday.
Via
Benzinga
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
July 01, 2022
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
June 30, 2022
Gainers
Via
Benzinga
Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session
June 30, 2022
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical...
Via
Benzinga
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
June 13, 2022
- Topline results expected in the second half of 2022 -
From
Dermata Therapeutics
Via
AccessWire
Dermata to Present at the H.C. Wainwright Global Investment Conference
May 23, 2022
SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 16, 2022
Dermata completes a $5.0 million private placement financing DMT310 Phase 2 rosacea trial topline results expected in H2 2022 SAN DIEGO, CA / ACCESSWIRE / May 16, 2022 / Dermata Therapeutics, Inc....
From
Dermata Therapeutics
Via
AccessWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
May 02, 2022
Via
Benzinga
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 25, 2022
SAN DIEGO, CA / ACCESSWIRE / April 25, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment of...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 21, 2022
SAN DIEGO, CA / ACCESSWIRE / April 21, 2022 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA) and (NASDAQ:DRMAW), a clinical-stage biotechnology company focusing on the treatment...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
March 28, 2022
DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022 DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023 DMT310 Phase...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
March 24, 2022
SAN DIEGO, CA / ACCESSWIRE / March 24, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and...
From
Dermata Therapeutics
Via
AccessWire
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 22, 2022
Gainers Palisade Bio (NASDAQ:PALI) shares rose 34.1% to $1.08 during Tuesday's regular session. Trading volume for this security as of 13:31 EST is 52.4 million, which...
Via
Benzinga
42 Stocks Moving in Monday's Pre-Market Session
March 07, 2022
Gainers Nine Energy Service, Inc. (NYSE: NINE) rose 96.7% to $3.54 in pre-market trading after climbing around 43% on Friday. Shares of low-priced energy stocks jumped as...
Via
Benzinga
75 Biggest Movers From Yesterday
March 22, 2022
Gainers NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares jumped 299.4% to close at $6.23 on Monday as the company received clearance from the FDA to initiate a pharmacokinetic...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 24, 2022
Gainers Unicycive Therapeutics (NASDAQ:UNCY
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 18, 2022
Gainers Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The market value of their outstanding shares is at $98.9...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 17, 2022
Gainers NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market session. The company's market cap stands at $48.5...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 11, 2022
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.6% to $1.35 during Friday's regular session. As of 12:30 EST, Dermata Therapeutics's stock is...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 11, 2022
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock rose 29.0% to $1.38 during Friday's pre-market session. The company's market cap stands at $11.4 million. Innoviva...
Via
Benzinga
62 Biggest Movers From Yesterday
February 11, 2022
Gainers American Rebel Holdings, Inc. (NASDAQ: AREB) shares jumped 42.8% to close at $3.07 on Thursday following the company's recent uplisting to the Nasdaq....
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
February 10, 2022
Gainers Avenue Therapeutics (NASDAQ:ATXI)...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
February 10, 2022
Gainers Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.1% to $1.35 during Thursday's regular session. The current volume of 17.5 million shares is 7266....
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
February 10, 2022
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 27.1% to $1.36 during Thursday's pre-market session. The company's market cap stands at $11.3...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
February 10, 2022
Good morning, trader! Rub that sleep out our your eyes because we're going over the biggest pre-market stock movers for Thursday!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
February 09, 2022
Gainers Doximity (NYSE:DOCS) shares increased by 23.7% to $61.61 during Wednesday's regular session. Doximity's stock is trading at a volume of 8.5 million shares...
Via
Benzinga
60 Biggest Movers From Yesterday
February 10, 2022
Gainers US Ecology, Inc. (NASDAQ: ECOL) shares surged 67.7% to close at $47.25 on Wednesday after Republic Services reported it will buy the company at $48 per share in cash....
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.